SPRINT and BP targets of anthypertensive treatment
The results of the Systolic Blood Pressure Intervention Trial (SPRINT) have been recently published (New England Journal of Medicine, November 9, 2015).
This was a large trial including 9361 participants with Systolic Blood Pressure (SBP) ≥130 mmHg and high cardiovascular risk but no diabetes or previous stroke. They were treated to a SBP target <120 mmHg (intensive treatment) or to a target <140 mmHg (standard treatment).
An interview with Prof. Josep Redon.
Josep Redon is Scientific Director of INCLIVA Research Institute, Hospital Clinico Universitario Valencia, University of Valencia. He is past-President of the European Society of Hypertension and has published over 300 articles in internationally recognized journals and is the author of more than ten books. He is a member of the editorial board of several international journals in the field of hypertension, such as Hypertension, Journal of Hypertension, Blood Pressure Monitoring.
In 2015 the ESH Excellence Centres celebrated 10 year of excellence in hypertension and cardiovascular prevention. The rationale for the ESH Excellence Centres was created and further elaborated at the ESH Educational Committee meeting in Italy in July 2005. The European Society of Hypertension (ESH) is making continuous efforts to manage the burden of hypertension in Europe by stimulating scientific exchange related to knowledge about hypertension, and supporting and building organizations committed to work for the control of hypertension.
Join a network of over 1300 hypertension professionals dedicated to scientific research and knowledge and to improving hypertension prevention, treatment and control.
– Eligibility to apply for ESH Hypertension Specialist status
– Eligibility to serve in a leadership capacity in an ESH Excellence Center
– Reduced Member registration fee for the ESH Annual Meeting
– Subscription to the Journal of Hypertension